Compare ADPT & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | CMRE |
|---|---|---|
| Founded | 2009 | 1974 |
| Country | United States | Monaco |
| Employees | N/A | 1880 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2019 | N/A |
| Metric | ADPT | CMRE |
|---|---|---|
| Price | $15.14 | $15.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 1 |
| Target Price | ★ $17.78 | $12.00 |
| AVG Volume (30 Days) | ★ 1.7M | 458.3K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.10% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $3.98 | N/A |
| Revenue Next Year | $22.72 | N/A |
| P/E Ratio | ★ N/A | $5.55 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $9.78 | $8.58 |
| 52 Week High | $20.76 | $18.06 |
| Indicator | ADPT | CMRE |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 38.35 |
| Support Level | $14.87 | $15.21 |
| Resistance Level | $15.27 | $17.76 |
| Average True Range (ATR) | 0.64 | 0.54 |
| MACD | 0.23 | -0.18 |
| Stochastic Oscillator | 88.33 | 23.65 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.